Regulus Therapeutics Inc (NASDAQ:RGLS) Releases Q1 Results: Stock Falls

May 13, 2022

Biopharmaceutical company Regulus Therapeutics Inc (NASDAQ:RGLS), which is involved on discovering and developing new age medicines that target microRNAs, was in the news yesterday. Trading Data On Thursday, RGLS stock fell 7.57% to $0.2456 with 6.80 million shares, compared to its average volume of 1.99 million shares. The stock moved within a range of $0.1860 – 0.2500 after opening trade at $0.2495. Regulus Therapeutics Reports First Quarter 2022 Financial Results…


Regulus Therapeutics (NASDAQ:RGLS): FDA Clears Trial: Stock Soars 55%

May 12, 2022

Regulus Therapeutics (NASDAQ:RGLS) soared 55% after the clinical-stage biotech firm disclosed that the FDA had accepted its RGLS8429 Investigational New Drug Application in hereditary kidney disorders. The IND application was submitted in order to obtain regulatory approval to examine RGLS8429 in hereditary autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetically based disease that is a leading cause of end-stage renal failure. Trading Data On Wednesday, RGLS stock soared…